profil
- Assistant at the 1st Hematology Clinic, Metropolitan General.
- Specialist Hematologist with experience in the Bone Marrow Transplantation Unit at “Evangelismos” General Hospital.
- Young EHA (European Hematology Association) Ambassador for Greece.
EDUCATION & ACADEMIC DEGREES
- Medical Degree, University of Patras, July 2014, graduated with honors (“Very Good” – 7.66/10).
- Master’s Degree, National and Kapodistrian University of Athens, in Bleeding – Thrombosis and Transfusion Medicine, graduated with Distinction (9.73/10).
- Successful completion of the European Hematology Association Examination (EHA Exam), Frankfurt.
- 2022–2023: Completion of the EHA Masterclass program.
WORK EXPERIENCE
- Rural service Doctor, P.I. Machairado – K.Y. Katastari – General Hospital of Zakynthos.Residency in Internal Medicine, 3rd Internal Medicine Clinic, 417 NIMTS Hospital.
- 2019–2022: Four-year Hematology specialization at the Hematology – Lymphoma Clinic and Bone Marrow Transplantation Unit, “Evangelismos” General Hospital.
- Specialist Hematologist (extended contract) at the Bone Marrow Transplantation Unit, “Evangelismos” General Hospital.
- 2023 – present: Assistant at the 1st Hematology Clinic, Metropolitan General.
MEMBERSHIPS & EDITORIAL BOARD
- Full member of the Hellenic Society of Hematology (EAE).
- Member of the European Hematology Association (EHA).
- Young EHA Ambassador for Greece.
RESEARCH PROJECTS
- Investigator in clinical studies, e.g.:
Non-interventional, prospective cohort study on the efficacy and safety of first-line Selinexor-based therapy in patients with relapsed/refractory multiple myeloma (RRMM) (2024–2026).
RECENT PUBLICATIONS
- Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients. BJH, DOI: 10.1111/bjh.20102
- Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Steroids (PolaRCHP) in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Real-Life Experience in Greece. Blood, DOI: 10.1182/blood-2024-211525
- Differential Gene Expression Profile in DNA Damage Signaling Pathways, in De Novo Acute Myeloid Leukemia Patients before Induction Chemotherapy. Blood, DOI: 10.1182/blood-2022-158980
